Last updated: May 3, 2026
ANNOVERA (segesterone acetate/ethinyl estradiol)
Clinical-trial status, market performance, and forward projections for ANNOVERA, with regulatory and competitive context for decision-making.
What is ANNOVERA and what indication does it cover?
ANNOVERA is a combined hormonal contraceptive administered as a monthly vaginal ring delivering segesterone acetate (SEG) and ethinyl estradiol (EE). It is approved for use by people with a uterus for pregnancy prevention (female contraception). The product is marketed by a multinational manufacturer under a branded regimen intended for cyclic use across a monthly cycle schedule (ring-in/ring-out).
What is the clinical-trials evidence base for ANNOVERA?
ANNOVERA’s clinical package is dominated by the pivotal Phase 3 program evaluating safety and effectiveness of a reusable, cyclic vaginal ring releasing SEG/EE.
Key efficacy and safety trial components
The evidence base includes:
- Pivotal Phase 3 effectiveness trial(s) in which pregnancy rates were evaluated using standard contraceptive endpoints (typical reporting includes Pearl Index-related metrics and life-table analyses).
- Longitudinal exposure consistent with repeated monthly use across multiple treatment cycles to characterize bleeding patterns, hormonal tolerability, and device performance over time.
- Contraceptive effectiveness endpoints designed for label compliance, supported by pharmacokinetic and drug release consistency across cycles.
Common clinical endpoints used in the package
The program addresses:
- Efficacy: pregnancy incidence under typical-use conditions aligned to contraceptive labeling conventions.
- Bleeding profile: frequency of scheduled bleeding and unscheduled bleeding/spotting.
- Adverse events: discontinuation rates, device-related effects, and class risks expected for combined hormonal contraception (e.g., thromboembolic risk considerations in labeling).
Sources: ANNOVERA US prescribing information and FDA-related review materials for the pivotal Phase 3 program. [1], [2]
What does the market look like for ANNOVERA today?
A market view requires (i) US contraception demand, (ii) the installed base of competing methods, and (iii) pricing and payer dynamics for brand products in a competitive field.
Market structure
The combined hormonal contraception market in the US is segmented by:
- Oral contraceptives (generic and brand share is large due to long-duration patent expiries)
- Transdermal patch
- Vaginal ring
- Long-acting reversible contraception (IUDs, implants) that compete for the same patient population
Within vaginal rings, ANNOVERA competes with other locally acting contraceptive technologies and the broader combined-method set.
Positioning drivers
ANNOVERA’s commercial thesis rests on:
- Reusable design (monthly use cadence that reduces pharmacy refill dependence versus daily oral methods)
- Predictable cyclic regimen that fits routine contraception behaviors
However, performance is moderated by:
- Formulary access (coverage tiering and prior authorization practices)
- Brand-to-generic pressure in oral contraceptives
- Patient and prescriber preference for long-acting methods
Sources: US prescribing information for product constraints and indication framing; FDA approval context; generic/competitive context anchored by contraception market dynamics reported in major market research and FDA labeling documentation. [1], [2]
How does ANNOVERA compare to major competitive contraceptive options?
Competitive pressure comes from both method-class substitutes and direct formulation substitutes.
Competitive landscape (US contraceptive methods)
- Vaginal ring competitors (including older ring technologies where applicable)
- Combined hormonal oral contraceptives (with high generic availability)
- Transdermal patch (brand and generic availability varies)
- Long-acting reversible contraception (LARC) (high efficacy, low adherence burden, strong guideline support)
Implications for ANNOVERA:
- ANNOVERA has a method advantage versus daily adherence alternatives.
- ANNOVERA faces displacement risk versus LARC in patient segments prioritizing maximal pregnancy prevention with minimal ongoing action.
Sources: FDA contraceptive labeling framework for method classes; prescribing information; FDA review and public product documentation. [1], [2], [3]
What regulatory milestones define ANNOVERA’s trajectory?
ANNOVERA’s commercial trajectory depends on:
- Initial approval and label scope
- Post-approval updates to warnings, contraindications, and use instructions
- Any safety communications affecting combined hormonal contraception classes
Regulatory anchor points
- US approval of ANNOVERA for contraception under the branded product label. [1]
- FDA clinical review documenting the pivotal efficacy and safety evidence used for approval. [2]
Clinical-trials update: what is the forward-looking evidence pipeline?
A clinical-trials update requires trial disclosures beyond the pivotal dataset: post-marketing studies, label expansion trials, or additional formulation/lifecycle studies.
For ANNOVERA, the core publicly documented clinical package remains the pivotal program used in the initial approval review materials and prescribing information.
Sources: ANNOVERA prescribing information and FDA review documentation. [1], [2]
What market projections should investors and planners model for ANNOVERA?
Projections in branded contraception must be modeled as a function of:
- Adoption rate (new users by method choice)
- Retention (continuation across 12 to 24 months)
- Formulary penetration (commercial coverage mix)
- Competitive displacement (LARC growth and oral generic substitution)
- Label and policy constraints that affect access
Scenario framework (operational planning)
Use three-way scenario design tied to coverage and method migration:
Base case (most likely)
- Growth is driven by:
- Incremental new users shifting from daily adherence methods
- Maintained formulary inclusion and physician familiarity
- Drag factors:
- Persistent LARC displacement pressure
- Ongoing generic oral contraceptive competition
Upside case
- Growth accelerates if:
- Coverage expands to more favorable tiers
- Patient adoption increases in markets where refill convenience matters
- Upside is limited if:
- LARC uptake continues to increase and captures a larger share of new starts
Downside case
- Growth slows if:
- Payers restrict coverage or shift to cheaper alternatives
- Patient and prescriber migration favors LARC due to adherence and preference trends
Quantitative projection approach
Because ANNOVERA’s exact net revenue trajectory depends on payer rebates, channel mix, and specific formulary status, a robust projection model should be anchored to:
- Total new starts for combined methods in the US
- Share of vaginal ring users
- ANNOVERA’s share within ring-based utilization
- Duration of use (ring reuse adherence)
- Price realization net of rebates
Sources: Clinical labeling constraints affecting use and discontinuation drivers; FDA review context; contraception competitive dynamics anchored by public FDA labeling and broader method-class substitution structure. [1], [2], [3]
Key business risks that can change projections
Method substitution risk
- Patients can switch to long-acting methods with high efficacy and low adherence burden.
Coverage and reimbursement risk
- Brand contraception depends on payer policy for tier placement and prior authorization.
Safety/class risks
- Combined hormonal contraception carries known class warnings; any amplified safety scrutiny can affect prescribing behavior.
Sources: ANNOVERA labeling and class warnings in prescribing information; FDA review documentation. [1], [2]
Key Takeaways
- ANNOVERA is a branded, reusable monthly vaginal ring for pregnancy prevention delivering segesterone acetate and ethinyl estradiol. [1]
- The clinical evidence underpinning approval relies on pivotal Phase 3 effectiveness and safety data evaluated over repeated cyclic use, with pregnancy prevention endpoints and bleeding profile characterization. [1], [2]
- Market growth for ANNOVERA should be modeled against the combined hormonal contraception category, with major headwinds from generic oral products and ongoing migration to LARC. [1], [3]
- Projection ranges should be scenario-based on formulary penetration, payer tier dynamics, and retention/adherence in monthly reuse.
- Core value drivers remain refill convenience versus daily oral contraception and method preference among ring users, constrained by payer access and LARC displacement. [1], [3]
FAQs
-
What active ingredients does ANNOVERA contain?
ANNOVERA contains segesterone acetate and ethinyl estradiol. [1]
-
What is the approved use of ANNOVERA?
ANNOVERA is indicated for pregnancy prevention (contraception). [1]
-
What did the FDA rely on for approval?
The FDA relied on the pivotal clinical evidence package showing contraceptive effectiveness and safety over repeated cycles documented in the FDA clinical review. [2]
-
What are the main competitive threats to ANNOVERA?
Competitive threats include generic combined oral contraceptives and long-acting reversible contraception uptake. [3]
-
What factors most affect ANNOVERA market performance?
Coverage and formulary access, patient continuation with cyclic use, and substitution to LARC and cheaper methods. [1], [3]
References (APA)
[1] ANNOVERA (segesterone acetate and ethinyl estradiol) prescribing information. (U.S. label).
[2] U.S. Food and Drug Administration. Clinical review for ANNOVERA (segesterone acetate and ethinyl estradiol).
[3] U.S. Food and Drug Administration. Drug and contraceptive labeling resources and background on contraceptive method classes (public FDA materials).
